Tourmaline Bio, Inc. (NASDAQ: TRML), a late-stage clinical biotechnology company, has announced positive topline results from its ongoing Phase 2 TRANQUILITY trial. The trial evaluates the efficacy of pacibekitug, an IL-6 inhibitor, in patients with elevated high-sensitivity C-reactive protein and chronic kidney disease. The study demonstrated rapid, deep, and durable reductions in high-sensitivity C-reactive protein (hs-CRP) levels through Day 90 across all pacibekitug arms, achieving statistical significance (p<0.0001) compared to placebo. Notably, the 50 mg quarterly dosing arm achieved over 85% reduction in hs-CRP from baseline. The adverse events in the trial were comparable to placebo. These results support advancing pacibekitug into a potential Phase 3 cardiovascular outcomes trial in atherosclerotic cardiovascular disease and a planned Phase 2 proof-of-concept trial for abdominal aortic aneurysm, expected to initiate in the second half of 2025.